Stock Pick

Category: Stock Market

  • Down 30% in 2022: Here’s why I’m holding tight to my Vulcan Energy shares

    A businessman hugs his computer.A businessman hugs his computer.

    Not many ASX lithium shares are as divisive as Vulcan Energy Resources Ltd (ASX: VUL). But, with many of its critics toting the company as both hopeful and exciting – albeit a long way from profitability – I’m holding onto my Vulcan shares.

    The $1 billion S&P/ASX 300 Index (ASX: XKO) lithium developer differs greatly from its ASX peers. It aims to produce the battery-making material while maintaining a net zero footprint.

    The company plans to use renewable energy from its geothermal and lithium brine resource to power its production.

    Additionally, the resource is located in Europe, where lithium resources are few and far between and demand for the material is expected to surge.

    Finally, the company aims to sell geothermal energy to the grid, thereby reducing Europe’s reliance on Russian energy.

    After all that spruiking, some might think Vulcan Energy sounds like the market’s best-kept secret. But that’s likely not the case.

    Unfortunately for investors like myself, the Vulcan Energy share price has struggled in recent times. It has dumped 31% year to date and 42% over the last 12 months to trade at $7.50 today.

    While there are plenty of reasons to be cautious when it comes to the lithium share, I’m still hopeful.

    The ups and downs of my investment

    My investment in Vulcan Energy was my first ASX share purchase. It’s likely no surprise, then, that I’ve learnt a lot in my time holding the stock. If I could have that time again, here’s what I’d want to know.

    Plenty of ASX 300 shares are yet to turn a profit, but red balance sheets bring additional risks. And as Vulcan Energy isn’t yet producing, the company is far from profitability.

    Sentiment for unprofitable companies generally shifts alongside market conditions. Inflationary environments are particularly likely to turn the market away from companies operating in the red.

    Investors should, therefore, be prepared to approach unprofitable stocks with realistic expectations of the potential volatility involved.

    Additionally, the company’s flagship Zero Carbon Lithium Project represents a world-first. Meaning there is plenty of potential for the company to experience major challenges along its journey to production.

    Finally, since Vulcan Energy was targeted by activist short seller J Capital in October 2021, the company’s short position has increased more than 500% to sit at 6.6% at last count.   

    That seemingly means the market is more pessimistic on the stock than it once was. While Warren Buffett encourages investors to ignore the crowd, such pessimism can be hard to stomach.

    I’m still bullish on Vulcan Energy shares

    With all that considered, I’m still happy with my investment in Vulcan Energy shares. And I’m not alone in expecting a bright future.

    Broker Alster Research has tipped the stock to reach $20, representing a potential 167% upside.

    Meanwhile, Medallion Financial Group’s Philippe Bui admits to being bullish on lithium, telling The Bull the company’s technology is “exciting”. However, as Bui prefers producers, he slapped Vulcan Energy shares with a sell.

    Such sentiment was earlier heralded by Red Leaf Securities’ John Athanasiou, who said, courtesy of the publication:

    In our view, favourable potential exists for Vulcan Energy to become a lithium producer with a zero-carbon footprint … Market sentiment has firmly moved towards conservative profitable operations. We prefer other stocks until sentiment towards risk improves.

    Vulcan Energy shares are a complicated investment and will likely experience ups and downs in the coming years, but I plan to stick around for the long haul.

    The post Down 30% in 2022: Here’s why I’m holding tight to my Vulcan Energy shares appeared first on The Motley Fool Australia.

    .

    More reading

    Motley Fool contributor Brooke Cooper has positions in Vulcan Energy Resources Limited. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    from The Motley Fool Australia https://ift.tt/X9tYRVv

  • 5 things to watch on the ASX 200 on Monday

    Business woman watching stocks and trends while thinking

    Business woman watching stocks and trends while thinking

    On Friday, the S&P/ASX 200 Index (ASX: XJO) finished another difficult week with a day in the red. The benchmark index sank 1.2% to 6,474.2 points.

    Will the market be able to bounce back from this on Monday? Here are five things to watch:

    ASX 200 expected to edge higher

    The Australian share market looks set to start the week with a small gain. This is despite another selloff on Wall Street on Friday. According to the latest SPI futures, the ASX 200 is expected to open the day 5 points or 0.1% higher this morning. On Wall Street, the Dow Jones was down 1.7%, the S&P 500 dropped 1.5%, and the NASDAQ also tumbled 1.5%.

    Oil prices tumble

    Energy producers such as Santos Ltd (ASX: STO) and Woodside Energy Group Ltd (ASX: WDS) could have a tough start to the week after oil prices tumbled on Friday. According to Bloomberg, the WTI crude oil price was down 2.15% to US$79.49 a barrel and the Brent crude oil price dropped 2.35% to US$85.15 a barrel. The deteriorating crude demand outlook weighed on prices.

    Ramsay rated neutral

    The Ramsay Health Care Limited (ASX: RHC) share price fell heavily in September after the private hospital operator’s takeover collapsed. However, the team at Goldman Sachs only believe that this leaves it trading at fair value. This morning the broker resumed coverage on the company with a neutral rating and $59.00 price target. Goldman notes that its “performance recovery [is] still impacted by Covid but with green shoots.”

    Gold price rises

    Gold miners including Newcrest Mining Limited (ASX: NCM) and Northern Star Resources Ltd (ASX: NST) could have a decent start to the week after the gold price edged higher. According to CNBC, the spot gold price was up 0.2% to US$1,672 an ounce on Friday night. However, this couldn’t stop the precious metal from having its worst quarter since March 2021.

    Telstra rated neutral

    Goldman Sachs is also sitting on the fence with the Telstra Corporation Ltd (ASX: TLS) share price following an update from the ACCC on the telco giant’s proposed agreement with TPG Telecom Ltd (ASX: TPG). The broker said: “We see slightly more uncertainty in the outcome of the MOCN agreement given balanced views expressed by the ACCC today.” Goldman has a neutral rating and $4.40 price target on Telstra’s shares.

    The post 5 things to watch on the ASX 200 on Monday appeared first on The Motley Fool Australia.

    .

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended Telstra Corporation Limited. The Motley Fool Australia has recommended Ramsay Health Care Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    from The Motley Fool Australia https://ift.tt/jnBEXGO

  • Analysts name 3 ASX growth shares to buy next week

    A businessman hugs his computer.

    A businessman hugs his computer.

    Are you looking to add some growth shares to your portfolio next week?

    If you are, three ASX growth shares that could be worth considering are listed below. Here’s why analysts are tipping them as buys:

    Airtasker Ltd (ASX: ART)

    The first ASX growth share for investors to look at next week is Airtasker. It is Australia’s leading online marketplace for local services, connecting people and businesses. While the company has been around for a decade, it is still barely even scratching the surface of its enormous market opportunity. Management estimates that it has a total addressable market of $600 billion across Australia, the UK, and the US. This compares to its Gross Marketplace Volume (GMV) of $189.6 million in FY 2022, which was up 23.8% on the prior year.

    Morgans is a fan and has an add rating and $1.05 price target on its shares.

    Altium Limited (ASX: ALU)

    Another ASX growth share for investors to look at when the market reopens is Altium. It is an an industry-leading printed circuit board (PCB) design software provider. PCBs are the boards you find inside almost all electronic devices and are integral to their operation. Thanks to Altium’s dominant position in the market, management is very confident in its outlook and is aiming to more than double its revenue to US$500 million by 2026.

    Jefferies is positive on the company. It currently has a buy rating and $38.13 price target on its shares.

    Aristocrat Leisure Limited (ASX: ALL)

    A final ASX growth share to consider next week is Aristocrat Leisure. It is one of the world’s leading gaming technology companies with a world class portfolio of poker machines and digital/mobile games. The latter includes games such as Cashman Casino, Gummy Drop, and RAID, which have helped the company amass ~20 million monthly active users. This is underpinning significant recurring revenues. Aristocrat is also undertaking a share buyback and looking to expand into the real money gaming market.

    Citi is a fan of the company and has a buy rating and $40.20 price target on its shares.

    The post Analysts name 3 ASX growth shares to buy next week appeared first on The Motley Fool Australia.

    .

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Altium. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Airtasker Limited. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    from The Motley Fool Australia https://ift.tt/4XQqEnf

  • 2 top ETFs for ASX investors to buy in October

    ETF written in yellow with a yellow underline and the full word spelt out in white underneath.

    ETF written in yellow with a yellow underline and the full word spelt out in white underneath.

    If you’re looking for an easy way to invest your hard-earned money, then exchange traded funds (ETFs) could be the answer.

    That’s because ETFs give you the opportunity to invest in a large group of shares in one fell swoop, which can be a great way to build a diverse portfolio.

    But which ETFs should you look at this month? Here are two popular ETFs that could be quality options right now:

    BetaShares NASDAQ 100 ETF (ASX: NDQ)

    The BetaShares NASDAQ 100 ETF could be worth considering in October. Particularly given its incredibly poor showing during September, which has left it trading around its lowest levels of the year.

    This ETF provides investors with access to the top 100 non-financial shares on the famous NASDAQ stock exchange. This includes the likes of Alphabet, Amazon, Apple, Meta, Microsoft, Netflix, Nvidia, and Tesla.

    BetaShares also highlights that with a strong focus on technology, the ETF provides investors with diversified exposure to a high-growth potential sector that is under-represented on the Australian share market.

    ETFS S&P Biotech ETF (ASX: CURE)

    Another ETF for investors to consider in October is the ETFS S&P Biotech ETF.

    This ETF gives investors exposure to the U.S. biotechnology sector. ETFS notes that these are companies that are engaged in the research, development and manufacturing of products based on genetic analysis and genetic engineering. This includes the development of immunotherapy treatments and vaccines to treat human diseases.

    Among its holdings you will find the likes of ChemoCentryx, Global Blood Therapeutics, and Twist Bioscience.

    A big fan of the ETF is Felicity Thomas from Shaw & Partners. She recently told Livewire:

    I like to buy ETFs for the long term. We have an ageing population, and what’s the most important thing in the world? Your health. Biotech, healthcare, and life sciences, that’s where you want to be invested over the next couple of decades.

    The post 2 top ETFs for ASX investors to buy in October appeared first on The Motley Fool Australia.

    .

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended BETANASDAQ ETF UNITS and ETFS S&P Biotech ETF. The Motley Fool Australia has positions in and has recommended BETANASDAQ ETF UNITS. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    from The Motley Fool Australia https://ift.tt/cuaegYC

  • The Qantas share price hit some turbulence in September

    poor flight centre share price represented by plane flying away from lightening storm

    poor flight centre share price represented by plane flying away from lightening storm

    The Qantas Airways Limited (ASX: QAN) share price suffered from headwinds in September, falling by around 5%.

    It’s still up by around 10% from the start of August, so it has just given back some of the recent gains that it has seen in the last couple of months.

    Qantas shares did manage to outperform the S&P/ASX 200 Index (ASX: XJO), which fell by around 7.5%.

    What happened in September?

    The airline wasn’t the only one suffering from volatility during last month.

    Investors are having to deal with the prospect of ongoing high inflation and the prospect of higher interest rates to bring it under control.

    Inflation increases the costs for businesses and could potentially decrease household (and business) demand for some services.

    Why do interest rates matter so much? Ray Dalio, the billionaire founder of Bridgewater Associates explains:

    It all comes down to interest rates. As an investor, all you’re doing is putting up a lump sum payment for a future cash flow.

    In other words, it’s essential for valuation purposes.

    Specifically on Qantas, it didn’t announce anything that it deemed to be price sensitive during the month.

    But, Qantas did announce that Stephanie Tully would be the new CEO of Jetstar. She has worked at Qantas since 2004 across a number of positions in progressively senior roles. Markus Svensson will take on the chief customer officer role and become a member of the group executive committee that reports to the CEO.

    Management commentary

    Talking about those appointments, Qantas CEO Alan Joyce said:

    These appointments come at an important time for us. The team is working incredibly hard to overcome challenges facing the whole industry as it gets back on its feet, and the data shows we’re almost there.

    Managing this kind of executive renewal internally means we keep our momentum and can leverage a huge amount of corporate knowledge, including through the transition.

    Stephanie has worked across several different parts of the airline, from crewing to marketing, and has a deep understanding of customer experience. She’s an outstanding leader and she’ll be leading a very experienced senior team at Jetstar to keep building on the strengths of that business.

    Markus has navigated incredible levels of complexity in recent years, managing most of the commercial elements of the Qantas network through several waves of lockdown and recovery, and also managing our relationships with alliance partners around the world.

    What is Qantas expecting in FY23?

    Sometimes, the outlook can have a significant impact on the Qantas share price (or any business).

    The fuel cost for FY23 is expected to be $5 billion, driven by a 60% increase in fuel prices compared to FY19.

    Qantas is working on a number of initiatives to offset the inflation it’s experiencing, with cost and revenue initiatives.

    The revenue per available seat kilometre is expected to fully recover increased fuel prices across the group as well as temporary unit cost increases associated with addressing its current operational challenges.

    The airline said it was going to reduce its domestic capacity by another 10 percentage points in response to higher fuel costs and operational challenges. Some capacity may be restored once “operational resilience” improves. In the first half of FY23, capacity will be 95% of pre-COVID levels and in the second half, it will be 106% of pre-COVID levels.

    In terms of international capacity, it will be 65% of pre-COVID levels in the FY23 first half and 84% in the second half of FY23.

    The Qantas loyalty division underlying earnings before interest and tax (EBIT) is expected to increase to between $425 million to $450 million for FY23. “Strong yields” are expected to moderate in the freight division of Qantas, but will be above pre-COVID levels.

    The post The Qantas share price hit some turbulence in September appeared first on The Motley Fool Australia.

    .

    More reading

    Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    from The Motley Fool Australia https://ift.tt/OlWv0sa

  • Goldman Sachs says these small cap ASX shares are buys

    A young woman sits with her hand to her chin staring off to the side thinking about her investments.

    A young woman sits with her hand to her chin staring off to the side thinking about her investments.

    If you’re looking for new investment options at the small side of town, then Goldman Sachs has your back.

    Listed below are a couple of small cap ASX shares that it recently put buy ratings on. Here’s what you need to know about them:

    Adairs Ltd (ASX: ADH)

    The first small cap ASX share that Goldman Sachs is tipping as a buy is Adairs.

    It is the leading furniture and homewares retailer behind the Adairs, Focus on Furniture, and Mocka brands.

    Goldman currently has a buy rating and $3.05 price target on its shares. It likes the company due to its loyal customer base and store expansion opportunity. It commented:

    The core Adairs business has a highly loyal customer base, and ongoing store roll-out opportunity: ADH is has a strong brand presence across Australia, a highly engaged and loyal customer base (>1mn Linen Lover members), and ongoing opportunity to roll out new and upsized stores. […] Attractive valuation and high dividend yield: we view valuation as undemanding with ADH trading on 6.9x FY23E P/E

    Temple & Webster Group Ltd (ASX: TPW)

    Another small cap ASX share that Goldman likes is Temple & Webster.

    Despite the company being an online rival to Adairs, the broker remains positive on both.

    It currently has a buy rating and $7.55 price target on its shares. Goldman likes Temple & Webster due to its leadership position in a market that is in the process of shifting online. Its analysts explained:

    We believe the business has a material runway for long-term growth, supported by a large and growing TAM driven by increasing e-commerce penetration which still lags other comparable markets (Aus 16% vs. UK/US 28%/25%), even after a large pull forward in online sales over the last 2-3 years. […] We believe TPW can deliver long term structural growth, despite a slowdown in the near term macro environment.

    The post Goldman Sachs says these small cap ASX shares are buys appeared first on The Motley Fool Australia.

    .

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended ADAIRS FPO and Temple & Webster Group Ltd. The Motley Fool Australia has positions in and has recommended ADAIRS FPO. The Motley Fool Australia has recommended Temple & Webster Group Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    from The Motley Fool Australia https://ift.tt/t49hClO

  • Why did the Imugene share price implode 31% in September?

    A disappointed lab researcher sits in her lab looking at her clipboard with her hand to her face as she worries about the Imugene share price todayA disappointed lab researcher sits in her lab looking at her clipboard with her hand to her face as she worries about the Imugene share price today

    The Imugene Limited (ASX: IMU) share price had a rough month despite multiple clinical trial updates.

    Imugene shares have fallen 30.77% from 26 cents at market close on 31 August to 18 cents at market close on 30 September.

    Let’s take a look at how the Imugene share price performed in September.

    Imugene shares fall

    Imugene shares have fallen in the past month even with multiple clinical trial updates from the company. However, the company has also conducted a major capital raise.

    Imugene is not the only pharmaceutical industry share on the ASX to have fall in September. The Telix Pharmaceuticals Ltd (ASX: TLX) share price has descended 24% since market close on 31 August. Immutep Ltd (ASX: IMM) shares fell 13% in the same time frame. Meanwhile, the S&P/ASX 200 Health Care Index (ASX: XHJ) has dropped 5% in the month.

    On 13 September, Imugene shares dropped amid an $80 million capital raise. The placement involved the issue of 400 million new ordinary shares at 20 cents per share. Imugene also offered a total of 200 million new options to placement subscribers at an exercise price of 33 cents per share. The share allotment date and issue of new options was 19 September.

    On 21 September, Imugene advised the first patient had been dosed in intravenous cohort 1 in the VAXINIA phase one clinical trial. Imugene CEO Leslie Chong said she was “very proud” of team and partners on the Vaxinia study.

    Then on 26 September, news emerged that Imugene had formed a partnership with Arovella Therapeutics Ltd (ASX: ALA). Arovella’s CAR19-iNKT cell therapy will be tested with Imugene’s onCARlytics platform with the aim of destroying solid cancer tumours.

    On a positive note, the Imugene share price increased 9% on 8 September. The company advised it has dosed the first patient in the nextHERIZON phase two clinical trial. The trial is investigating the use of Imugene’s HER-Vaxx in patients with HER-2+ gastric cancer.

    Imugene share price snapshot

    The Imugene share price has lost 63% in the past year, while it has fallen 58% year to date.

    For perspective, the ASX 200 health care index has shed 11% in the year to date.

    Imugene has a market capitalisation of about $1.13 billion based on the current share price.

    The post Why did the Imugene share price implode 31% in September? appeared first on The Motley Fool Australia.

    .

    More reading

    Motley Fool contributor Monica O’Shea has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    from The Motley Fool Australia https://ift.tt/NF7pRah

  • Another interest rate hike coming Tuesday: almost every expert

    Young man in shirt and tie staring at his laptop screen watching the Paladin Energy share price tank todayYoung man in shirt and tie staring at his laptop screen watching the Paladin Energy share price tank today

    With the S&P/ASX 200 Index (ASX: XJO) down 7% over the past month and 15.5% lower than where it started this year, investors have enough to worry about.

    But many Australians will return from their October long weekends to a rude shock.

    On Tuesday, the board of the Reserve Bank of Australia will meet. Unfortunately, according to comparison website Finder, 97% of experts say the RBA will once again raise its cash rate.

    Australians have barely caught their breaths since the last hike, but the RBA is forecast to apply an incredible sixth consecutive month of interest rate increases for consumers and businesses.

    “The cash rate is still below the ‘neutral’ levels,” said Metropole Property Strategists director Michael Yardney.

    “If the RBA is genuinely keen to stomp on inflation, they must raise rates further.”

    Another 50 basis point hike expected 

    Finder’s study found the majority of finance experts, 56%, are expecting a 50 basis point increase to the rate on Tuesday.

    Finder consumer research head Graham Cooke estimated that from May to now, all the interest rate rises have added almost $8,000 to the annual cost of a typical $500,000 home loan.

    “Another 50 basis point hike will push that cost up to near $10,000,” he said.

    “With one-in-four (26%) Aussie homeowners already struggling to pay their mortgage in September, this could be the rate rise that pushes some borrowers to the limit.”

    With less money to spend, businesses will see reduced demand for their goods and services.

    This could potentially mean a continued downwards spiral for ASX shares.

    Cooke said mortgages are not the only point of pressure for Australian households.

    “With the fuel excise ending on 30 September, and the cost of groceries, energy and travel prices all skyrocketing, this housing blow will be especially painful for many.”

    According to loan comparison site Mozo, the last time the RBA made such a long series of rate hikes was between October 2009 to November 2010 in the aftermath of the global financial crisis.

    But those increases only came in increments of 25 basis points.

    What will happen after Tuesday?

    Cooke said that while the majority of economic experts expect the rate hikes to pause in November, RBA would “likely” resume early in the new year.

    “Despite a slight softening in August, we’ll likely see the inflation rate spike back up.”

    AMP Ltd (ASX: AMP) chief economist Dr Shane Oliver is expecting a 25 basis point hike on Tuesday, but would not be surprised if it’s higher.

    “After five rate hikes in a row, the RBA should be slowing the pace of rate hikes to be able to assess the impact of rate hikes to date and allow for monetary policy lags,” he said.

    “But the risk is high that it will go with another 0.5% hike given the excessive focus on backward-looking inflation and jobs data and the hawkishness evident in other major global central banks. A 0.4% hike would be a nice compromise.”

    Ord Minnett head of institutional research Malcolm Wood thought the RBA might be done after Tuesday.

    “I expect the RBA to pause its tightening cycle in November,” he said.

    “With fiscal tightening from Chalmers first budget, Europe in recession and the US soon to follow, this should end the tightening cycle.”

    The post Another interest rate hike coming Tuesday: almost every expert appeared first on The Motley Fool Australia.

    .

    More reading

    Motley Fool contributor Tony Yoo has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    from The Motley Fool Australia https://ift.tt/p5v6bFt

  • Top brokers name 3 ASX shares to buy next week

    Broker written in white with a man drawing a yellow underline.

    Broker written in white with a man drawing a yellow underline.

    Last week saw a number of broker notes hitting the wires once again. Three buy ratings that investors might want to be aware of are summarised below.

    Here’s why brokers think investors ought to buy them next week:

    AGL Energy Limited (ASX: AGL)

    According to a note out of Credit Suisse, its analysts have upgraded this energy company’s shares to an outperform rating with a $8.20 price target. This follows the announcement of the company’s plan to exit coal 10 years ahead of schedule in 2035. Credit Suisse appears supportive on the move. And while it expects this to lead to a decent increase in capital expenditures, the broker believes AGL’s free cash flow will remain strong. The AGL share price ended the week at $6.84.

    BHP Group Ltd (ASX: BHP)

    A note out of Macquarie reveals that its analysts have retained their outperform rating and lifted their price target on this mining giant’s shares to $44.00. Macquarie has increased its thermal coal price forecasts to reflect supply constraints and global energy security risks. This has led to the broker bumping its earnings estimates for BHP by approximately 5% per annum through to FY 2026. The BHP share price was fetching $38.52 at Friday’s close.

    Brickworks Limited (ASX: BKW)

    Analysts at Morgans have retained their add rating and lifted their price target on this building products company’s shares to $24.00. According to the note, Morgans was impressed with Brickworks’ full year results, which came in ~10% ahead of consensus estimates. In addition, the broker highlights that its shares screen as cheap. This is based on the current discount to inferred NTA and the pipeline of value accretive projects that will potentially be realised over the coming years. The Brickworks share price ended the week at $21.54.

    The post Top brokers name 3 ASX shares to buy next week appeared first on The Motley Fool Australia.

    .

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Brickworks. The Motley Fool Australia has positions in and has recommended Brickworks. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    from The Motley Fool Australia https://ift.tt/lPiTD2m

  • Brokers name 2 top ASX dividend shares to buy this month

    A female stockbroker reviews share price performance in her office with the city shown in the background through her windows

    A female stockbroker reviews share price performance in her office with the city shown in the background through her windows

    Are you looking for more dividend shares to buy? If you are, you may want to check out the two listed below that have been rated as buys by brokers.

    Here’s what you need to know about these top ASX dividend shares:

    Healthco Healthcare and Wellness REIT (ASX: HCW)

    According to a recent note out of Goldman Sachs, its analysts have put a conviction buy rating and $2.08 price target on this real estate investment trust’s shares.

    Goldman likes Healthco Healthcare and Wellness REIT, which has a focus on hospitals, aged care, childcare, life sciences, and primary care properties, due to its robust balance sheet, favourable tenant mix, the resilience of healthcare and childcare assets, and the expected strong future demand for assets across the care spectrum.

    In addition, the broker is expecting some attractive yields from its shares in the coming years. It has pencilled in dividends per share of 7.5 cents in both FY 2023 and FY 2024. Based on the current Healthco Healthcare and Wellness REIT unit price of $1.39, this will mean yields of 5.4% for investors.

    Super Retail Group Ltd (ASX: SUL)

    A recent note out of Morgans reveals that its analysts have retained their add rating on this retail conglomerate’s shares with an improved price target of $13.00.

    Morgans remains positive on the company and is expecting a solid first half to FY 2023. Particularly given its “much more resilient earnings in FY22 than had been forecast” and the fact that there are “no signs yet that the consumer is pulling back in Australia.”

    The broker is expecting this to underpin further generous dividend payments for this financial year and beyond. It is forecasting fully franked dividends per share of 56 cents in FY 2023 and 58 cents in FY 2024. Based on the latest Super Retail share price of $8.88, this will mean yields of 6.3% and 6.5%, respectively.

    The post Brokers name 2 top ASX dividend shares to buy this month appeared first on The Motley Fool Australia.

    .

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Super Retail Group Limited. The Motley Fool Australia has positions in and has recommended Super Retail Group Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    from The Motley Fool Australia https://ift.tt/LelgIVG